Yabing Mai

3.7k total citations · 1 hit paper
20 papers, 2.6k citations indexed

About

Yabing Mai is a scholar working on Oncology, Surgery and Molecular Biology. According to data from OpenAlex, Yabing Mai has authored 20 papers receiving a total of 2.6k indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Oncology, 9 papers in Surgery and 4 papers in Molecular Biology. Recurrent topics in Yabing Mai's work include Bladder and Urothelial Cancer Treatments (9 papers), Cancer Immunotherapy and Biomarkers (9 papers) and Urinary and Genital Oncology Studies (4 papers). Yabing Mai is often cited by papers focused on Bladder and Urothelial Cancer Treatments (9 papers), Cancer Immunotherapy and Biomarkers (9 papers) and Urinary and Genital Oncology Studies (4 papers). Yabing Mai collaborates with scholars based in United States, Netherlands and Canada. Yabing Mai's co-authors include Joaquim Bellmunt, Dean F. Bajorin, Toni K. Choueiri, Ronald de Wit, Rodolfo F. Perini, Jae‐Lyun Lee, Daniel P. Petrylak, David I. Quinn, David J. Vaughn and Yves Fradet and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and Annals of Oncology.

In The Last Decade

Yabing Mai

18 papers receiving 2.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma

2017 2.4k citations Joaquim Bellmunt, Ronald de Wit et al. New England Journal of Medicine profile →

Peers

Countries citing papers authored by Yabing Mai

Since Specialization

Citations

This map shows the geographic impact of Yabing Mai's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yabing Mai with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yabing Mai more than expected).

Fields of papers citing papers by Yabing Mai

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yabing Mai. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yabing Mai. The network helps show where Yabing Mai may publish in the future.

Co-authorship network of co-authors of Yabing Mai

This figure shows the co-authorship network connecting the top 25 collaborators of Yabing Mai. A scholar is included among the top collaborators of Yabing Mai based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yabing Mai. Yabing Mai is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Mechanistic insights into taxane-induced psychiatric adverse events: a global pharmacovigilance and experimental investigation 2025 ·Molecular Psychiatry ·Anqi Lin, Yabing Mai, Guichuan Lai, Zhengrui Li, Junyi Shen, (unknown), Nan Zhang, (unknown), Kailai Li, (unknown), Bicheng Ye, Aimin Jiang, Peng Luo, (unknown), (unknown)	0
2	A triple-mode strategy on JQ1-loaded nanoplatform for superior antitumor therapy in pancreatic cancer 2025 ·Materials Today Bio ·Zhiguo Li, (unknown), Zhiwen Liu, Wei Li, Yabing Mai, Hao Fu, Guotao Yuan, (unknown)	1
3	Comment on “Non-Proportional Hazards – an Evaluation of the MaxCombo Test in Cancer Clinical Trials” by the Cross-Pharma Non-Proportional Hazards Working Group 2023 ·Statistics in Biopharmaceutical Research ·Ray Lin, Pralay Mukhopadhyay, Satrajit Roychoudhury, Keaven M. Anderson, Tianle Hu, Bo Huang, Larry Léon, Jason J. Z. Liao, Ji Lin, Rong Liu, Xiaodong Luo, Yabing Mai, Rui Qin, Kay Tatsuoka, Yang Wang, Jiabu Ye, Jian Zhu, Tai‐Tsang Chen, Renee Iacona, (unknown)	1
4	A Flexible Ensemble Learning Method for Survival Extrapolation 2022 ·Therapeutic Innovation & Regulatory Science ·Ran Dai, (unknown), Meijing Wu, Yabing Mai, (unknown)	0
5	Endometriosis-Related Pain Reduction During Bleeding and Nonbleeding Days in Women Treated with Elagolix 2021 ·Journal of Pain Research ·Sanjay K. Agarwal, Sukhbir S. Singh, David F. Archer, Yabing Mai, Kristof Chwalisż, Keith Gordon, Eric S. Surrey	6
6	Teasing Out the Overall Survival Benefit With Adjustment for Treatment Switching to Multiple Treatments 2021 ·Statistics in Biopharmaceutical Research ·Yuqing Xu, Meijing Wu, Weili He, Qiming Liao, Yabing Mai	1
7	Baseline endometriosis-associated pain burden: Data from 1600+ women enrolled in elagolix clinical trials 2019 ·Journal of Endometriosis and Pelvic Pain Disorders ·Nicholas Leyland, Stephanie J. Estes, Samantha Eichner, Ahmed M. Soliman, Yabing Mai, Michael C. Snabes, Hugh S. Taylor, Eric S. Surrey	1
8	Health-Related Quality-of-Life Analysis From KEYNOTE-045: A Phase III Study of Pembrolizumab Versus Chemotherapy for Previously Treated Advanced Urothelial Cancer 2018 ·Journal of Clinical Oncology ·David J. Vaughn, Joaquim Bellmunt, Yves Fradet, Jae‐Lyun Lee, Lawrence Fong, Nicholas J. Vogelzang, Miguel Ángel Climent, Daniel P. Petrylak, Toni K. Choueiri, Andrea Necchi, Winald R. Gerritsen, Howard Gurney, David I. Quinn, Stéphane Culine, Cora N. Sternberg, Yabing Mai, Haojie Li, Rodolfo F. Perini, Dean F. Bajorin, Ronald de Wit	86
9	Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma breakdown → 2017 ·New England Journal of Medicine ·Joaquim Bellmunt, Ronald de Wit, David J. Vaughn, Yves Fradet, Jae‐Lyun Lee, Lawrence Fong, Nicholas J. Vogelzang, Miguel Ángel Climent, Daniel P. Petrylak, Toni K. Choueiri, Andrea Necchi, Winald R. Gerritsen, Howard Gurney, David I. Quinn, Stéphane Culine, Cora N. Sternberg, Yabing Mai, Christian Poehlein, Rodolfo F. Perini, Dean F. Bajorin	2374
10	Pembrolizumab (pembro) versus paclitaxel, docetaxel, or vinflunine for recurrent, advanced urothelial cancer (UC): Mature results from the phase 3 KEYNOTE-045 trial 2017 ·Annals of Oncology ·Ronald de Wit, David J. Vaughn, Yves Fradet, Jia-Lin Lee, Lawrence Fong, Nicholas J. Vogelzang, José A. Martínez-Climent, Daniel P. Petrylak, Toni K. Choueiri, Andrea Necchi, Winald R. Gerritsen, Howard Gurney, David I. Quinn, Stéphane Culine, Cora N. Sternberg, Yabing Mai, Markus Puhlmann, Rodolfo F. Perini, Joaquim Bellmunt, Dean F. Bajorin	6
11	Health-related quality of life (HRQoL) in the KEYNOTE-045 study of pembrolizumab versus investigator-choice chemotherapy for previously treated advanced urothelial cancer. 2017 ·Journal of Clinical Oncology ·David J. Vaughn, Joaquim Bellmunt, Ronald de Wit, Yves Fradet, Jae‐Lyun Lee, Lawrence Fong, Nicholas J. Vogelzang, Miguel Ángel Climent, Daniel P. Petrylak, Toni K. Choueiri, Andrea Necchi, Winald R. Gerritsen, Howard Gurney, David I. Quinn, Stéphane Culine, Cora N. Sternberg, Yabing Mai, Haojie Li, Rodolfo F. Perini, Dean F. Bajorin	9
12	Planned survival analysis from KEYNOTE-045: Phase 3, open-label study of pembrolizumab (pembro) versus paclitaxel, docetaxel, or vinflunine in recurrent, advanced urothelial cancer (UC). 2017 ·Journal of Clinical Oncology ·Dean F. Bajorin, Ronald de Wit, David J. Vaughn, Yves Fradet, Jae‐Lyun Lee, Lawrence Fong, Nicholas J. Vogelzang, Miguel Ángel Climent, Daniel P. Petrylak, Toni K. Choueiri, Andrea Necchi, Winald R. Gerritsen, Howard Gurney, David I. Quinn, Stéphane Culine, Cora N. Sternberg, Yabing Mai, Markus Puhlmann, Rodolfo F. Perini, Joaquim Bellmunt	17
13	Pembrolizumab vs investigator-choice chemotherapy for previously treated advanced urothelial cancer: Phase 3 KEYNOTE-045 study 2017 ·European Journal of Cancer ·Andrea Necchi, Joaquim Bellmunt, Ronald de Wit, David J. Vaughn, Yves Fradet, (unknown), Loren G. Fong, N. Vogelzang, M.Á. Climent, Daniel P. Petrylak, Toni K. Choueiri, Winald R. Gerritsen, Howard Gurney, David I. Quinn, Stéphane Culine, C. Sternberg, Yabing Mai, Markus Puhlmann, Rodolfo F. Perini, Dean F. Bajorin	3
14	Health-related quality of life (HRQoL) of pembrolizumab (pembro) vs chemotherapy (chemo) for previously treated advanced urothelial cancer (UC) in KEYNOTE-045. 2017 ·Journal of Clinical Oncology ·Ronald de Wit, Dean F. Bajorin, Joaquim Bellmunt, Yves Fradet, Jae‐Lyun Lee, Lawrence Fong, Nicholas J. Vogelzang, Miguel Ángel Climent, Daniel P. Petrylak, Toni K. Choueiri, Andrea Necchi, Winald R. Gerritsen, Howard Gurney, David I. Quinn, Stéphane Culine, Cora N. Sternberg, Yabing Mai, Haojie Li, Rodolfo F. Perini, David J. Vaughn	7
15	A Quantitative Approach for Benefit-Risk Assessment Using Stochastic Multi-Criteria Discriminatory Method 2016 ·Statistics in Biopharmaceutical Research ·Yaping Wang, Yabing Mai, Weili He	4
16	KEYNOTE-045: Randomized phase 3 trial of pembrolizumab (MK-3475) versus paclitaxel, docetaxel, or vinflunine for previously treated metastatic urothelial cancer. 2015 ·Journal of Clinical Oncology ·Joaquim Bellmunt, Guru Sonpavde, Ronald de Wit, Toni K. Choueiri, Arlene O. Siefker‐Radtke, Elizabeth R. Plimack, Nicole Lewis, Holly Brown, Yabing Mai, Christine K. Gause, David R. Kaufman, Dean F. Bajorin	11
17	KEYNOTE-052: Phase 2 study of pembrolizumab (MK-3475) as first-line therapy for patients (pts) with unresectable or metastatic urothelial cancer ineligible for cisplatin-based therapy. 2015 ·Journal of Clinical Oncology ·Dean F. Bajorin, Elizabeth R. Plimack, Arlene O. Siefker‐Radtke, Toni K. Choueiri, Ronald de Wit, Guru Sonpavde, (unknown), Holly Brown, Yabing Mai, Lei Pang, Rodolfo F. Perini, Joaquim Bellmunt	9
18	Effect of angiotensin receptor blockade on insulin sensitivity and endothelial function in abdominally obese hypertensive patients with impaired fasting glucose 2011 ·Clinical Science ·Todd S. Perlstein, Robert R. Henry, Kieren J. Mather, Michael R. Rickels, Nicola Abate, Scott M. Grundy, Yabing Mai, Jeanine Albu, (unknown), James L. Pool, Mark A. Creager	26
19	A Meta-analysis to Assess the FDA DAVP’s TLOVR Algorithm in HIV Submissions 2011 ·Drug Information Journal ·F. M. Smith, Thomas Hammerstrom, (unknown), Susan Zhou, (unknown), Yabing Mai, Kimberly Struble, Mohammad F. Huque	46
20	Effects of the renin inhibitor MK-8141 (ACT-077825) in patients with hypertension 2010 ·Journal of the American Society of Hypertension ·Charlotte Jones-Burton, Joseph Rubino, Sophie Roy, Yabing Mai, Alan G. Meehan, M Bellet, Peter U. Feig	6

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact